FDA Panel Rejects Lipocine's Testosterone Pill Post author:Sam Post published:January 10, 2018 Post category:BioPharma The FDA voted six in favor and thirteen against the benefit/risk profile of TLANDO. Source: BioSpace You Might Also Like TherapeuticsMD Announces Webcast Of Investor Day On March 1 February 15, 2017 Integer CEO Steps Down March 29, 2017 Invenra Appoints Vice President, Corporate Development May 15, 2017
